当前位置: 首页 > >

Meticrane-DataSheet-MedChemExpress

发布时间:

Product Data?Sheet
Meticrane
Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage: HY-B0908 1084-65-7 C??H??NO?S? 275.34 Sodium Channel; Chloride Channel Membrane Transporter/Ion Channel Powder In solvent -20°C 4°C -80°C -20°C 3 years 2 years 6 months 1 month

Inhibitors ? Agonists ? Screening Libraries

Solvent & Solubility
In Vitro 10 mM in DMSO Mass 1 mg 5 mg 10 mg

Solvent Concentration Preparing Stock Solutions 5 mM 10 mM 1 mM

3.6319 mL 0.7264 mL 0.3632 mL

18.1594 mL 3.6319 mL 1.8159 mL

36.3187 mL 7.2637 mL 3.6319 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY
Description Meticrane is a diuretic. Meticrane inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension. IC?? & Target In Vivo Sodium and chloride ion[1] Meticrane, a thiazide diuretic is highly ranked in the connectivity map (cMap) analysis, and it does not have any known anti-cancer or immune-stimulating effect. Co-treatment with Meticrane significantly enhances treatment efficacy of CTLA-4 blockade[2].

PROTOCOL
Animal Mice[2]

1

www.MedChemExpress.com

Administration [2]

Meticrane is dissolved in DMSO to a concentration of 160 mg/mL. BALB/c (H-2d) mice receive daily i.p. injections at a dose of 400 mg/kg bodyweight for 10 days post anti-CTLA4 treatment. The thiazide diuretic Meticrane is used at doses of 150-300 mg once daily; the reported LD50 for mice is 10 g/kg after i.p. administration. 3 groups of standard BALB/c mice are treated consecutively (n=3/group) with increasing doses of Meticrane i.p. (100 mg/kg; 200 mg/kg and 400 mg/kg) for 10 days and monitored weight and general wellbeing. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES
[1].?Rumiko TANAKA, et al. Crystal Structure of Meticrane. ANALYTICAL SCIENCES 2007, VOL. 23. [2].?Lesterhuis WJ, et al. Network analysis of immunotherapy-induced regressing tumours identifies novel synergisticdrug combinations. Sci Rep. 2015 Jul 21;5:12298.

Caution: Product has not been fully validated for medical applications. For research use only. Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

2

www.MedChemExpress.com




友情链接: